The global next generation cancer diagnostics market size was valued at USD 16.61 billion in 2024 and is expected to reach USD 41.44 billion by 2033, growing at a CAGR of 11.15% from 2025 to 2033. This anticipated growth is largely driven by the increasing incidence of oncology diseases worldwide, the rising need for accurate prognosis and early diagnosis of various cancer types, and growing efforts by key industry players to develop innovative and efficient diagnostic solutions. As the demand for more precise and timely cancer detection continues to increase, advancements in diagnostic technologies are becoming essential to improving patient outcomes.

Traditionally, cancer diagnosis has involved several tests such as physical examinations, laboratory testing, imaging tests, and biopsies. Each stage of this diagnostic pathway follows a structured clinical approach designed to minimize potential complications while supporting accurate prognosis and treatment decision-making by oncologists. This process underscores the vital importance of diagnostic accuracy throughout the entire oncology lifecycle, often holding greater significance than the therapeutic regimen itself, as early and precise detection directly influences treatment success.

Next-generation sequencing (NGS) has emerged as a transformative technology in cancer diagnostics, offering the ability to perform comprehensive genomic profiling of tumors. This allows clinicians to identify actionable mutations and molecular alterations that guide patients toward targeted therapies, supporting the growing shift toward personalized medicine and improved clinical outcomes. Despite its potential, the widespread impact of NGS in routine clinical care still requires more structured evidence and strategic integration. Not all patients with actionable mutations ultimately receive targeted therapies due to several barriers. These include delays in sequencing within the care pathway, challenges in physician interpretation of genomic data, limited accessibility to advanced testing, and concerns regarding cost-effectiveness. Addressing these factors remains essential for unlocking the full clinical and economic value of NGS-driven diagnostics.

Key Market Trends & Insights:

• North America dominated the next-generation cancer diagnostics market, accounting for a 40.17% revenue share in 2024. This strong regional position is supported by advanced healthcare infrastructure, rapid adoption of cutting-edge diagnostic technologies, substantial investment in oncology research, and the presence of leading industry players. Within the region, the U.S. is expected to register the highest CAGR from 2025 to 2033, driven by increasing demand for precision diagnostics, expanded clinical use of genomic testing, and ongoing innovation in cancer detection methods.

• By technology, the next-generation sequencing (NGS) segment held the highest market share of 37.26% in 2024, highlighting the critical role of genomic profiling and mutation analysis in modern oncology. The growing emphasis on personalized medicine and targeted therapies continues to reinforce the dominant position of NGS-based diagnostics.

• By application, the biomarker development segment led the market with a 42.18% share in 2024, reflecting the rising importance of biomarkers in improving early detection, predicting treatment response, and guiding therapy selection. Biomarker-driven insights are increasingly shaping clinical decisions across multiple cancer types.

• Based on function, the therapeutic monitoring segment accounted for the highest market share of 25.84% in 2024. This segment's prominence is driven by the growing need to track treatment effectiveness, monitor disease progression, and adjust therapy plans based on real-time diagnostic data. Therapeutic monitoring is becoming a key component in ensuring optimal outcomes for cancer patients undergoing advanced treatments.

Order a free sample PDF of the Next Generation Cancer Diagnostics Market Intelligence Study, published by Grand View Research.

Market Size & Forecast:

• 2024 Market Size: USD 16.61 Billion

• 2033 Projected Market Size: USD 41.44 Billion

• CAGR (2025-2033): 11.15%

• North America: Largest market in 2024

Key Companies & Market Share Insights:

Key players operating in the next-generation cancer diagnostics market are actively pursuing a range of initiatives aimed at strengthening their competitive position and expanding the accessibility of their products and services. These companies are increasingly focusing on strategies such as geographic expansion, portfolio enhancement, and forming strategic partnerships with healthcare providers, research institutions, and technology developers. Such collaborative and expansion-oriented efforts are proving essential in driving market growth, enabling broader adoption of advanced diagnostic solutions, and ensuring that innovative testing technologies reach a wider patient population.

Key Players

• Janssen Pharmaceuticals, Inc.

• Illumina, Inc.

• Novartis AG

• F. Hoffmann-La Roche Ltd

• Koninklijke Philips N.V.

• QIAGEN

• Agilent Technologies, Inc. (Dako)

• Abbott

• Thermo Fisher Scientific Inc.

• GE HealthCare.

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

The next-generation cancer diagnostics market is expected to expand significantly over the forecast period, driven by increasing demand for advanced diagnostics to support early and precise cancer detection. Growth is supported by innovation in genomic technologies, technological integration such as AI and multi-omics, and the development of new diagnostic tools that improve clinical decision-making. Collaboration between industry players, regulatory support, and the shift toward more personalized and decentralized testing solutions are further propelling market adoption. Overall, advancements in next-generation diagnostics are enhancing the ability to detect and monitor cancer, thereby improving patient care and outcomes.